Name: Muscular Disorders Drug Development Summit
Start: 2027-01-26
End: 2027-01-28
Location: Hotel Commonwealth Boston

OVERVIEW

Muscular Disorders Drug Development Summit is organized by Hanson Wade and will be held from Jan 26 - 28, 2027 at Hotel Commonwealth Boston, Boston, Massachusetts, United States of America.

Description:
Strengthening Translational & Clinical Development of a New Wave of Genetic, Stem Cell, Small Molecule & RNA-Based Muscle Disease Therapies
After a year marked by uncertainty around Sarepta's Elevidys, the field is on the verge of new era shaped by cross-modality innovation and meaningful progress, with FDA submissions anticipated from Regenxbio, Capricor and Avidity that could transform therapeutic options for muscular dystrophies.

With investments including Servier’s $2.65 billion buyout of Edgewise signposting reignited pharma interest and funding opportunities, muscle disease drug developers are poised to double down on investments across their preclinical, translational and clinical programs in 2026 and beyond.

Take advantage of this timely opportunity to join 60+ industry experts spanning muscle disease biology, translation, clinical development and more at the Muscular Disorders Drug Development Summit for three days of focused collaboration designed to:

Explore emerging modalities beyond gene therapy
Discover lessons learnt from developers of approved drugs
Enhance biomarker measurements of muscular function and activity
Innovate more targeted delivery to specific muscles while avoiding off-target tissues
Leverage real-world data to uncover patient-relevant endpoints

With momentum building, don’t miss your chance to learn from Servier, Dyne Therapeutics, Sanofi, Biogen, Avidity Biosciences and more at the only forum dedicated to addressing biopharma’s most pressing challenges in advancing novel therapies for muscular dystrophies, Pompe disease and related myopathies.

Explore the Full Event Guide: